News | September 27, 2011

Occlutech CEO Wins Patent Lawsuit by St Jude-AGA Medical

September 27, 2011 — Occlutech announced its CEO, Tor Peters, has obtained a favorable ruling from the district court in Düsseldorf in patent litigation initiated personally against him by St. Jude AGA Medical. Occlutech is a European developer of implants for treating structural heart disease.

On May 10, 2011, Occlutech GmbH won a patent lawsuit that lasted more than five years, initiated by St. Jude-AGA Medical at the German Supreme Court in Karlsruhe regarding infringement of patent EP 808 138.

In further proceedings at the Regional Court in Düsseldorf, St. Jude-AGA Medical accused Peters privately for alleged violation of patent EP 808 138. In a ruling dated Sept. 8, 2011, this claim has now also been rejected by the District Court in Düsseldorf. The ruling is subject to appeal by St. Jude-AGA Medical.

Peters says, "It is amazing and quite shocking to see a company that you would normally consider ethical, going to such length in trying to kill a competitor by also going after private individuals with this kind of massive and unjustified litigation. Obviously we are very happy that the courts in Germany now ruled in our favor as courts in the U.K., the Netherlands and Sweden have done before."

Occlusion devices are used to treat structural heart disease, including structural heart defects and abnormalities such as atrial septal defects, (ASD), and patent foramen ovale (PFO), in minimally invasive, non-surgical procedures. The market for PFO occluders is expected to expand significantly as the link between PFO and stroke — the third most common cause of death — as well as severe migraine, becomes increasingly well documented.

For more information: www.occlutech.com


Related Content

News | Structural Heart Occluders

June 20, 2024 — atHeart Medical, a medical device company establishing a new standard of care for atrial septal defects ...

Home June 20, 2024
Home
News | Structural Heart Occluders

July 14, 2023 — In recent years, transcatheter intervention techniques have emerged as a promising alternative for the ...

Home July 14, 2023
Home
News | Structural Heart Occluders

May 5, 2022 – Joe DiMaggio Children’s Hospital recently announced the successful treatment of a patient with atrial ...

Home May 05, 2022
Home
News | Structural Heart Occluders

October 4, 2021 — U.S. Food and Drug Administration (FDA) has cleared the Abbott Amplatzer Talisman PFO Occlusion System ...

Home October 04, 2021
Home
Feature | Structural Heart Occluders | By Dave Fornell, Editor

September 20, 2021 — Abbott announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Portico ...

Home September 20, 2021
Home
News | Structural Heart Occluders

April 20, 2021 — Start-up medical device company atHeart Medical announced it is initiating its U.S. investigational ...

Home April 20, 2021
Home
Videos | Structural Heart Occluders

Interview with Carey Kimmelstiel, M.D., FACP, FACC, director, cardiac catheterization laboratory, director ...

Home March 24, 2020
Home
Technology | Structural Heart Occluders

June 10, 2019 – W. L. Gore & Associates (Gore) announced the U.S. Food and Drug Administration’s (FDA’s) premarket ...

Home June 10, 2019
Home
News | Structural Heart Occluders

March 27. 2019 — A newly released expert consensus statement provides recommendations for the safe and effective ...

Home March 27, 2019
Home
News | Structural Heart Occluders

February 13, 2019 — Le Bonheur Children's Hospital cardiologists in Memphis, Tenn., implanted the Amplatzer Piccolo ...

Home February 13, 2019
Home
Subscribe Now